Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) completed a registered direct offering that raised $2.5 million in gross proceeds, with the potential for an additional $4.6 million if associated warrants are exercised.

The Staten Island-based biopharmaceutical company sold 825,085 shares of common stock at $3.03 per share. The company also issued short-term warrants to purchase up to 1,650,170 additional shares at an exercise price of $2.78 per share in a concurrent private placement.

The warrants become exercisable immediately upon issuance and expire 24 months after the effective date of the registration statement covering the underlying shares. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.

Acurx stated it intends to use the net proceeds for working capital and general corporate purposes. The company noted that no assurance can be given that the short-term warrants will be exercised.

The shares were offered under a shelf registration statement filed with the Securities and Exchange Commission in July 2025 that became effective in January 2026. The short-term warrants were issued under a private placement exemption and have not been registered under the Securities Act.

Acurx develops antibiotics for difficult-to-treat bacterial infections, with its lead product candidate ibezapolstat targeting C. difficile infections. The company describes itself as Phase 3 ready to advance to international clinical trials, subject to obtaining appropriate financing.